The CAR-T (Chimeric Antigen Receptor-T cells) technology represents a great scientific breakthrough and a paradigm shift in the way severe diseases could be treated. Getting this technology from a promising scientific discovery to an actual benefit for patients and the society does, however, involve many processes and stakeholders and requires a partnership across many areas of expertise.
 
Here, we at Janssen will educate on the CAR-T technology with the aim to facilitate this partnership, by explaining the promise this technology brings, the logistics it demands, and the innovative thinking required at all levels by all stakeholders.